Literature DB >> 16436273

Antioxidative function and biodistribution of [Gd@C82(OH)22]n nanoparticles in tumor-bearing mice.

Jiangxue Wang1, Chunying Chen, Bai Li, Hongwei Yu, Yuliang Zhao, Jin Sun, Yufeng Li, Gengmei Xing, Hui Yuan, Jun Tang, Zhen Chen, Huan Meng, Yuxi Gao, Chang Ye, Zhifang Chai, Chuanfeng Zhu, Baocheng Ma, Xiaohong Fang, Lijun Wan.   

Abstract

Oxidative stress is considered to be one of the important mechanisms involved in carcinogenesis. In our previous study, gadolinium endohedral metallofullerenol ([Gd@C82(OH)22]n nanoparticles) have shown high inhibitory activity on hepatoma cell (H22) growth in mice. To explore the antioxidative functions of nanoparticles, we investigated the biodistribution of [Gd@C82(OH)22]n nanoparticles, the changes of blood coagulation profiles, the metabolism of reactive oxygen species (ROS) in the tumor-bearing mice as well as the possible relationships between nanoparticles treatment and ROS production in this paper. The activities of hepatic superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), glutathione S-transferase (GST) and catalase (CAT) as well as the levels of reduced glutathione (GSH), protein-bound thiols and malondialdehyde (MDA) were compared between the tumor-bearing mice and normal mice. Transplanted tumors were grown in mice by subcutaneous injection of murine hepatoma cells in the mice. The comparison of the above parameters between nanoparticles and cyclophosphamide (CTX) therapy were also investigated. [Gd@C82(OH)22]n administration can efficiently restore the damaged liver and kidney of the tumor-bearing mice. All the activities of enzymes and other parameters related to oxidative stress were reduced after [Gd@C82(OH)22]n treatment and tended closely to the normal levels. The results suggest that [Gd@C82(OH)22]n nanoparticle treatment could regulate ROS production in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436273     DOI: 10.1016/j.bcp.2005.12.001

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  25 in total

Review 1.  Tumor ablation and nanotechnology.

Authors:  Rachel L Manthe; Susan P Foy; Nishanth Krishnamurthy; Blanka Sharma; Vinod Labhasetwar
Journal:  Mol Pharm       Date:  2010-10-07       Impact factor: 4.939

Review 2.  Diverse Applications of Nanomedicine.

Authors:  Beatriz Pelaz; Christoph Alexiou; Ramon A Alvarez-Puebla; Frauke Alves; Anne M Andrews; Sumaira Ashraf; Lajos P Balogh; Laura Ballerini; Alessandra Bestetti; Cornelia Brendel; Susanna Bosi; Monica Carril; Warren C W Chan; Chunying Chen; Xiaodong Chen; Xiaoyuan Chen; Zhen Cheng; Daxiang Cui; Jianzhong Du; Christian Dullin; Alberto Escudero; Neus Feliu; Mingyuan Gao; Michael George; Yury Gogotsi; Arnold Grünweller; Zhongwei Gu; Naomi J Halas; Norbert Hampp; Roland K Hartmann; Mark C Hersam; Patrick Hunziker; Ji Jian; Xingyu Jiang; Philipp Jungebluth; Pranav Kadhiresan; Kazunori Kataoka; Ali Khademhosseini; Jindřich Kopeček; Nicholas A Kotov; Harald F Krug; Dong Soo Lee; Claus-Michael Lehr; Kam W Leong; Xing-Jie Liang; Mei Ling Lim; Luis M Liz-Marzán; Xiaowei Ma; Paolo Macchiarini; Huan Meng; Helmuth Möhwald; Paul Mulvaney; Andre E Nel; Shuming Nie; Peter Nordlander; Teruo Okano; Jose Oliveira; Tai Hyun Park; Reginald M Penner; Maurizio Prato; Victor Puntes; Vincent M Rotello; Amila Samarakoon; Raymond E Schaak; Youqing Shen; Sebastian Sjöqvist; Andre G Skirtach; Mahmoud G Soliman; Molly M Stevens; Hsing-Wen Sung; Ben Zhong Tang; Rainer Tietze; Buddhisha N Udugama; J Scott VanEpps; Tanja Weil; Paul S Weiss; Itamar Willner; Yuzhou Wu; Lily Yang; Zhao Yue; Qian Zhang; Qiang Zhang; Xian-En Zhang; Yuliang Zhao; Xin Zhou; Wolfgang J Parak
Journal:  ACS Nano       Date:  2017-03-14       Impact factor: 15.881

3.  [Gd@C(82)(OH)(22)](n) nanoparticles inhibit the migration and adhesion of glioblastoma cells.

Authors:  Jing Wang; Feng Gu; Ting Ding; Xiaoli Liu; Gengmei Xing; Yuliang Zhao; Ning Zhang; Yongjie Ma
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

4.  Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis.

Authors:  Xing-Jie Liang; Huan Meng; Yingze Wang; Haiyong He; Jie Meng; Juan Lu; Paul C Wang; Yuliang Zhao; Xueyun Gao; Baoyun Sun; Chunying Chen; Genmei Xing; Dingwu Shen; Michael M Gottesman; Yan Wu; Jun-Jie Yin; Lee Jia
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-05       Impact factor: 11.205

5.  Biomedical activities of endohedral metallofullerene optimized for nanopharmaceutics.

Authors:  Jie Meng; Dong-liang Wang; Paul C Wang; Lee Jia; Chunying Chen; Xing-Jie Liang
Journal:  J Nanosci Nanotechnol       Date:  2010-12

6.  Dendro[C(60)]fullerene DF-1 provides radioprotection to radiosensitive mammalian cells.

Authors:  Corey A Theriot; Rachael C Casey; Valerie C Moore; Linsey Mitchell; Julia O Reynolds; Madeline Burgoyne; Ranga Partha; Janice L Huff; Jodie L Conyers; Antony Jeevarajan; Honglu Wu
Journal:  Radiat Environ Biophys       Date:  2010-06-27       Impact factor: 1.925

7.  Trimetallic Nitride Endohedral Fullerenes Carboxyl-Gd3N@C80: A New Theranostic Agent for Combating Oxidative Stress and Resolving Inflammation.

Authors:  Tinghui Li; Li Xiao; Jiezuan Yang; Mengmeng Ding; Zhiguo Zhou; Leslie LaConte; Li Jin; Harry C Dorn; Xudong Li
Journal:  ACS Appl Mater Interfaces       Date:  2017-05-19       Impact factor: 9.229

Review 8.  Biopharmaceutics and therapeutic potential of engineered nanomaterials.

Authors:  Xing-Jie Liang; Chunying Chen; Yuliang Zhao; Lee Jia; Paul C Wang
Journal:  Curr Drug Metab       Date:  2008-10       Impact factor: 3.731

9.  Facile preparation of a new gadofullerene-based magnetic resonance imaging contrast agent with high 1H relaxivity.

Authors:  Chunying Shu; Frank D Corwin; Jianfei Zhang; Zhijian Chen; Jonathan E Reid; Minghao Sun; Wei Xu; Jae Hyun Sim; Chunru Wang; Panos P Fatouros; Alan R Esker; Harry W Gibson; Harry C Dorn
Journal:  Bioconjug Chem       Date:  2009-06       Impact factor: 4.774

Review 10.  Biological characterizations of [Gd@C82(OH)22]n nanoparticles as fullerene derivatives for cancer therapy.

Authors:  Jie Meng; Xingjie Liang; Xiaoyuan Chen; Yuliang Zhao
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.